<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006093</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068098</org_study_id>
    <secondary_id>NABTT-9911</secondary_id>
    <secondary_id>JHOC-NABTT-9911</secondary_id>
    <nct_id>NCT00006093</nct_id>
  </id_info>
  <brief_title>EMD 121974 in Treating Patients With Progressive or Recurrent Glioma</brief_title>
  <official_title>A Phase I/II Trial of EMD 121974 for Treatment of Patients With Recurrent Anaplastic Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Brain Tumor Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of EMD 121974 in treating patients who&#xD;
      have progressive or recurrent malignant glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of EMD 121974 in&#xD;
           patients with progressive or recurrent malignant glioma.&#xD;
&#xD;
        -  Determine the 6-month progression-free survival, clinical response rate, duration of&#xD;
           progression-free survival, and overall survival in patients treated with this drug.&#xD;
&#xD;
        -  Determine the effects of this drug on tumor perfusion, measured with magnetic resonance&#xD;
           perfusion scan, and markers for angiogenesis in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6-12 patients receive escalating doses of EMD 121974 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which more than 2&#xD;
      of 6 or 4 of 12 patients experience dose-limiting toxicity. Once the MTD is determined,&#xD;
      additional patients are treated at the MTD.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A minimum of 6 patients will be accrued for phase I of this study within&#xD;
      2-3 months. A total of 23-38 patients will be accrued for phase II of this study within 5-10&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilengitide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant glioma that is progressive or recurrent after&#xD;
             radiotherapy and/or chemotherapy&#xD;
&#xD;
               -  Eligible subtypes:&#xD;
&#xD;
                    -  Anaplastic astrocytoma&#xD;
&#xD;
                    -  Anaplastic oligodendroglioma&#xD;
&#xD;
                    -  Glioblastoma multiforme&#xD;
&#xD;
               -  Prior low-grade glioma that has progressed to a high-grade glioma (by biopsy)&#xD;
                  after radiotherapy and/or chemotherapy allowed&#xD;
&#xD;
          -  Measurable disease by volumetric and magnetic resonance perfusion scan&#xD;
&#xD;
          -  Prior biopsy or resection of recurrent brain tumor allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No advanced coronary artery disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serious concurrent infection or medical illness that would preclude study&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated carcinoma in&#xD;
             situ or basal cell skin cancer&#xD;
&#xD;
          -  No history of wound healing disorders&#xD;
&#xD;
          -  No peptic ulcer disease within the past year&#xD;
&#xD;
          -  Mini mental score of at least 15&#xD;
&#xD;
          -  Willing and able to undergo MRI&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior corticosteroids allowed if on stable dose for at least 5 days prior to study&#xD;
&#xD;
          -  Concurrent corticosteroids (e.g., dexamethasone) allowed as clinically needed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 months since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior surgery and recovered&#xD;
&#xD;
          -  No concurrent elective surgery or dental extractions&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis B. Nabors, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284-7811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007 May 1;25(13):1651-7. doi: 10.1200/JCO.2006.06.6514.</citation>
    <PMID>17470857</PMID>
  </results_reference>
  <results_reference>
    <citation>Nabors LB, Rosenfeld SS, Mikkelsen T, et al.: NABTT 9911: a phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. [Abstract] Neuro-Oncology 6 (4): TA-39, 379, 2004.</citation>
  </results_reference>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

